Molecular Imaging for Systemic Sclerosis-interstitial Lung Disease
Overview
Overview
Authors
Authors
Affiliations
Affiliations
Soon will be listed here.
References
1.
Volkmann E
. Natural History of Systemic Sclerosis-Related Interstitial Lung Disease: How to Identify a Progressive Fibrosing Phenotype. J Scleroderma Relat Disord. 2021; 5(2 Suppl):31-40.
PMC: 7943063.
DOI: 10.1177/2397198319889549.
View
2.
Tashkin D, Roth M, Clements P, Furst D, Khanna D, Kleerup E
. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med. 2016; 4(9):708-719.
PMC: 5014629.
DOI: 10.1016/S2213-2600(16)30152-7.
View
3.
Steen V, Conte C, Owens G, Medsger Jr T
. Severe restrictive lung disease in systemic sclerosis. Arthritis Rheum. 1994; 37(9):1283-9.
DOI: 10.1002/art.1780370903.
View
4.
Bergmann C, Distler J, Treutlein C, Tascilar K, Muller A, Atzinger A
. Ga-FAPI-04 PET-CT for molecular assessment of fibroblast activation and risk evaluation in systemic sclerosis-associated interstitial lung disease: a single-centre, pilot study. Lancet Rheumatol. 2024; 3(3):e185-e194.
DOI: 10.1016/S2665-9913(20)30421-5.
View
5.
Tashkin D, Volkmann E, Tseng C, Kim H, Goldin J, Clements P
. Relationship between quantitative radiographic assessments of interstitial lung disease and physiological and clinical features of systemic sclerosis. Ann Rheum Dis. 2014; 75(2):374-81.
DOI: 10.1136/annrheumdis-2014-206076.
View